NextCure Inc (FRA:2US)
€ 0.783 -0.138 (-14.98%) Market Cap: 22.04 Mil Enterprise Value: -45.05 Mil PE Ratio: 0 PB Ratio: 0.30 GF Score: 28/100

NextCure Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 12, 2022 / 07:00PM GMT
Release Date Price: €4.64 (-1.47%)
Gil Blum
Needham & Company, LLC - Analyst

Good afternoon and welcome to day two of the Annual Needham & Company Healthcare Conference. My name is Gil Blum, and I am a senior biotech analyst here at Needham & Company, covering immuno-oncology and the gene therapy subsectors. It is my pleasure to have with me today Michael Richman, CEO of NextCure. (Conference Instructions) And with that, Mike, the stage is yours.

Michael Richman
NextCure, Inc. - President & CEO

Great. Well, thank you so much, Gil. It's a real pleasure to be here, and I'd like to thank your team at Needham for the opportunity to present NextCure today.

So hopefully everyone can see my slides. NextCure started a little over six years ago with a vision towards developing next-generation immuno medicines. On this next slide, these are our forward-looking statements. Let me jump to slide 3 which outlines NextCure's highlights.

We call this slide our three Ps. It focuses on our pipeline, our product strategy, and our people. I will be walking through our pipeline

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot